Impairment in systemic IL-12 levels associated with increased expression of TGF-β1 and CTLA-4 in tumor and infiltrated immune cells may represent a putative signature of pesticide-induced immune impairment in breast cancer that should be considered when calculating the risk of recurrence and death of these patients. This evidence concerns the gene CTLA4 and breast cancer.